Charles River Laboratories (CRL) - Total Liabilities
Based on the latest financial reports, Charles River Laboratories (CRL) has total liabilities worth $4.74 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Charles River Laboratories net asset momentum to track the company's year-over-year net asset growth rate.
Charles River Laboratories - Total Liabilities Trend (1998–2025)
This chart illustrates how Charles River Laboratories's total liabilities have evolved over time, based on quarterly financial data. See Charles River Laboratories (CRL) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Charles River Laboratories Competitors by Total Liabilities
The table below lists competitors of Charles River Laboratories ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TORAY INDUSTRIES ADR/2
F:6HK
|
Germany | €1.52 Trillion |
|
Vanguard International Semiconductor
TWO:5347
|
Taiwan | NT$116.88 Billion |
|
Petro Rio S.A.
SA:PRIO3
|
Brazil | R$36.48 Billion |
|
Shenyang Fortune Precision Equipment Co. Ltd. A
SHG:688409
|
China | CN¥4.39 Billion |
|
Bentley Systems Inc
NASDAQ:BSY
|
USA | $2.30 Billion |
|
China Merchants Shekou Industrial Zone Holdings
SHE:001979
|
China | CN¥589.81 Billion |
|
ALSTOM S.A. UNSP.ADR 1/10
F:AOMU
|
Germany | €23.93 Billion |
|
Novatek Microelectronics Corp
TW:3034
|
Taiwan | NT$31.74 Billion |
Liability Composition Analysis (1998–2025)
This chart breaks down Charles River Laboratories's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Charles River Laboratories market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.36 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.61 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Charles River Laboratories's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Charles River Laboratories (1998–2025)
The table below shows the annual total liabilities of Charles River Laboratories from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.92 Billion | -2.39% |
| 2024-12-31 | $4.02 Billion | -11.37% |
| 2023-12-31 | $4.54 Billion | -0.94% |
| 2022-12-31 | $4.58 Billion | +3.32% |
| 2021-12-31 | $4.43 Billion | +32.42% |
| 2020-12-31 | $3.35 Billion | +10.60% |
| 2019-12-31 | $3.03 Billion | +20.21% |
| 2018-12-31 | $2.52 Billion | +34.93% |
| 2017-12-31 | $1.87 Billion | +0.42% |
| 2016-12-31 | $1.86 Billion | +42.60% |
| 2015-12-31 | $1.30 Billion | +10.34% |
| 2014-12-31 | $1.18 Billion | +20.50% |
| 2013-12-31 | $979.96 Million | -0.32% |
| 2012-12-31 | $983.14 Million | -4.47% |
| 2011-12-31 | $1.03 Billion | -1.48% |
| 2010-12-31 | $1.04 Billion | +25.82% |
| 2009-12-31 | $830.27 Million | -13.56% |
| 2008-12-31 | $960.47 Million | +2.01% |
| 2007-12-31 | $941.57 Million | -1.21% |
| 2006-12-31 | $953.11 Million | +35.87% |
| 2005-12-31 | $701.48 Million | -38.71% |
| 2004-12-31 | $1.14 Billion | +252.43% |
| 2003-12-31 | $324.75 Million | -0.20% |
| 2002-12-31 | $325.40 Million | +21.03% |
| 2001-12-31 | $268.86 Million | -4.10% |
| 2000-12-31 | $280.35 Million | -40.72% |
| 1999-12-31 | $472.89 Million | +619.90% |
| 1998-12-31 | $65.69 Million | -- |
About Charles River Laboratories
Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in … Read more